Stock TFX TELEFLEX INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Teleflex Incorporated

Equities

TFX

US8793691069

Medical Equipment, Supplies & Distribution

Market Closed - Nyse
Other stock markets
 04:00:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
206.7 USD 0.00% Intraday chart for Teleflex Incorporated +0.07% -17.10%
Apr. 15 Truist Securities Adjusts Teleflex Price Target to $240 From $265, Hold Rating Kept MT
Apr. 02 Teleflex Incorporated Introduces the UroLift? 2 System with Advanced Tissue Control, A Revolutionary Unified Platform Designed to Treat All Prostate Types CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,428 19,165 15,388 11,709 11,717 9,736 - -
Enterprise Value (EV) 1 19,035 21,268 16,793 13,129 13,309 10,270 9,702 11,134
P/E ratio 38.4 x 58 x 32.1 x 32.5 x 33.1 x 27.2 x 19.9 x 17.9 x
Yield 0.36% 0.33% 0.41% 0.54% 0.55% 0.66% 0.67% 0.67%
Capitalization / Revenue 6.71 x 7.55 x 5.48 x 4.2 x 3.94 x 3.15 x 2.98 x 2.82 x
EV / Revenue 7.33 x 8.38 x 5.98 x 4.7 x 4.47 x 3.32 x 2.97 x 3.23 x
EV / EBITDA 25.9 x 30.3 x 19.6 x 16 x 15.6 x 11.6 x 10.1 x 11 x
EV / FCF 56.9 x 61.4 x 28.9 x 49.8 x 31.7 x 19.2 x 14.9 x 14.9 x
FCF Yield 1.76% 1.63% 3.46% 2.01% 3.16% 5.21% 6.7% 6.69%
Price to Book 5.84 x 5.76 x 4.19 x 2.91 x 2.66 x 2.04 x 1.86 x -
Nbr of stocks (in thousands) 46,296 46,567 46,845 46,906 46,993 47,101 - -
Reference price 2 376.4 411.6 328.5 249.6 249.3 206.7 206.7 206.7
Announcement Date 2/20/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,595 2,537 2,810 2,791 2,974 3,093 3,265 3,447
EBITDA 1 734.2 701.1 858.4 820.1 855.5 884.4 961.1 1,013
EBIT 1 670.1 632.6 786.7 753.6 788.2 821.2 890.9 965.3
Operating Margin 25.82% 24.93% 28% 27% 26.5% 26.55% 27.28% 28.01%
Earnings before Tax (EBT) 1 - 357.7 559.5 445.9 434 547.3 679.1 751.5
Net income 1 461.5 335.3 485.4 363.1 356.3 365 500.5 577.5
Net margin 17.78% 13.22% 17.28% 13.01% 11.98% 11.8% 15.33% 16.75%
EPS 2 9.800 7.090 10.23 7.680 7.530 7.597 10.41 11.58
Free Cash Flow 1 334.4 346.4 580.5 263.6 420.2 534.7 649.7 745
FCF margin 12.88% 13.66% 20.66% 9.45% 14.13% 17.29% 19.9% 21.62%
FCF Conversion (EBITDA) 45.55% 49.41% 67.63% 32.15% 49.12% 60.46% 67.6% 73.51%
FCF Conversion (Net income) 72.46% 103.32% 119.6% 72.59% 117.94% 146.46% 129.81% 129.02%
Dividend per Share 2 1.360 1.360 1.360 1.360 1.360 1.365 1.375 1.390
Announcement Date 2/20/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 700.3 761.9 641.7 704.5 686.8 758 710.9 743.3 746.4 773.9 727.1 773 775.8 817.6 766.1
EBITDA 1 217.3 228.2 182.2 209.9 200 228.9 201.7 216.1 218.8 219.1 202.8 220.2 222.5 242.8 220.4
EBIT 1 199.4 210.3 164.9 193.7 184.4 211.5 183.4 197.7 202.8 203.5 186.2 203.5 206.1 225 202
Operating Margin 28.48% 27.6% 25.7% 27.5% 26.86% 27.9% 25.8% 26.6% 27.17% 26.3% 25.61% 26.32% 26.56% 27.52% 26.37%
Earnings before Tax (EBT) 1 - - 93.34 - 119.2 109.4 97.48 127 - 59.97 164.7 181.3 182.9 205.3 186.2
Net income 1 199.2 128.1 77.14 105.5 101.9 78.59 76.75 111.3 137.1 31.1 78.5 93.95 95.85 108 95
Net margin 28.44% 16.81% 12.02% 14.98% 14.84% 10.37% 10.8% 14.98% 18.37% 4.02% 10.8% 12.15% 12.35% 13.21% 12.4%
EPS 2 4.200 2.700 1.630 2.230 2.160 1.660 1.620 2.350 2.900 0.6600 1.672 1.978 2.015 2.408 1.990
Dividend per Share 2 0.3400 0.3400 - 0.3400 0.3400 0.3400 0.3400 0.3400 0.3400 0.3400 0.3400 0.3400 0.3400 0.3400 0.3400
Announcement Date 10/28/21 2/24/22 4/28/22 7/28/22 10/27/22 2/23/23 5/4/23 8/3/23 11/2/23 2/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,608 2,103 1,405 1,419 1,592 534 - 1,398
Net Cash position 1 - - - - - - 34 -
Leverage (Debt/EBITDA) 2.19 x 2.999 x 1.637 x 1.731 x 1.861 x 0.6037 x - 1.379 x
Free Cash Flow 1 334 346 581 264 420 535 650 745
ROE (net income / shareholders' equity) 19% 16% 17.8% 15.9% 8.42% 11.2% 11.7% 10%
ROA (Net income/ Total Assets) 8.34% 7.5% 9.02% 8.95% 4.93% 3.5% 5.2% 5.9%
Assets 1 5,532 4,471 5,384 4,056 7,230 10,430 9,626 9,788
Book Value Per Share 2 64.50 71.50 78.30 85.70 93.90 101.0 111.0 -
Cash Flow per Share 2 - 9.240 13.80 7.250 10.80 15.60 17.40 17.90
Capex 1 103 90.7 71.6 79.2 91.4 96.3 102 110
Capex / Sales 3.96% 3.57% 2.55% 2.84% 3.07% 3.11% 3.12% 3.2%
Announcement Date 2/20/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Teleflex Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
206.7 USD
Average target price
262.4 USD
Spread / Average Target
+26.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
TELEFLEX INCORPORATED Stock Teleflex Incorporated
-17.10% 9.74B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. TFX Stock
  4. Financials Teleflex Incorporated